| Code | CSB-RA025141MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to GB-0895, targeting thymic stromal lymphopoietin (TSLP), a critical epithelial-derived cytokine that plays a central role in initiating and sustaining type 2 inflammatory responses. TSLP is produced by epithelial cells in response to environmental triggers, allergens, and tissue damage, where it activates dendritic cells and promotes the differentiation of naive T cells toward a Th2 phenotype. Elevated TSLP expression is strongly associated with allergic diseases including asthma, atopic dermatitis, eosinophilic esophagitis, and chronic rhinosinusitis, making it an important therapeutic target for understanding type 2 inflammation.
GB-0895, also known as tezepelumab, is a human IgG2λ monoclonal antibody that blocks TSLP from interacting with its heterodimeric receptor complex. This biosimilar antibody provides researchers with a valuable tool for investigating TSLP-mediated signaling pathways, exploring mechanisms of allergic inflammation, and developing experimental models of type 2 immune responses. It supports studies examining epithelial-immune cell crosstalk and the upstream regulation of allergic cascades.
There are currently no reviews for this product.